From Financial Modeling Prep: 2025-06-17 21:00:00

On June 17, 2025, Malik Fady Ibraham, Executive Vice President of Research & Development at Cytokinetics (NASDAQ:CYTK), sold 2,000 shares at $32.91 each, holding 140,610 shares post-transaction.

Cytokinetics granted stock options and RSUs to 11 new employees on June 15, 2025, issuing 83,583 shares in options and 56,334 RSUs to attract talent.

Despite these efforts, Cytokinetics faces financial challenges with a negative P/E ratio of -6.27, high price-to-sales ratio of 202.21, and negative earnings yield of -15.96%.



Read more at Financial Modeling Prep:: Cytokinetics Incorporated’s Recent Financial and O…